Based on epidemiological data and the European Medicines Agency’s decision to communicate findings to healthcare professionals, SAHPRA has recommended that the prescribing information of medroxyprogesterone acetate be amended to reflect an increased risk of meningioma with higher dose preparations. 

Whilst there is a significantly higher relative risk, because meningioma is a rare condition, the absolute risk remains very low.

Patients will need to make an informed decision regarding the best contraceptive choice for their individual circumstances, taking into account the multitude of risks that can also be associated with pregnancy.

Read the SAHRPA notice here.